Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METRO-BIBF: Metronomic cyclophosphamide with or without nintedanib in recurrent ovarian cancer
2011-005814-12Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Cyclophosphamide + nintedanib with Cyclophosphamide + placebo (2 arms). Primary endpoint: Overall survival. Started Jul 2013; status: completed.
02
Drugs
nintedanib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2011-005814-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005814-12.